# SynGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syngen

- Industry: Medical Devices & Equipment
- Headquarters: San Carlos, US
- Website: www.syngeninc.com
- Total disclosed funding: $5M
- Latest round: Series A (Apr 18, 2012)
- Investors on record: 1

## About

SynGen Inc. develops advanced cell separation tools and accessories for regenerative medicine workflows, enhancing the efficiency and efficacy of therapeutic cell isolation processes for researchers and healthcare professionals.SynGen Inc. specializes in creating innovative solutions for cell separation and isolation in the regenerative medicine industry. Founded in San Carlos, US, the company has raised USD 5.00 mn through multiple funding rounds, with its most recent round being a Venture Debt of USD 2.50 mn from GE Capital in October 2014. The company has completed a total of 3 deals since its inception.SynGen Inc. specializes in the development of advanced cell separation tools and accessories tailored for regenerative medicine workflows. The company’s core product offerings include innovative devices designed for the efficient separation and isolation of therapeutic cells, which enhance the recovery of target cells while minimizing contamination from unwanted cells. These products aim to improve the overall productivity and efficacy of cell therapy processes, streamlining workflows for researchers and clinicians in the field. The end users predominantly consist of medical researchers, clinical laboratories, and healthcare professionals involved in regenerative medicine and cell therapy applications. SynGen’s products are marketed to various geographical regions, including North America, Europe, and Asia, addressing the diverse needs of the global regenerative medicine community.SynGen Inc. operates with a revenue model that centers around business-to-business (B2B) transactions, providing its products and services directly to research institutions, clinical settings, and medical organizations. The company facilitates sales through direct orders or partnerships with distributors, ensuring broad accessibility to its innovative separation systems. Transactions involve bulk purchases of equipment and accessories, as well as ongoing service agreements for maintenance and support. Specific pricing details for SynGen’s products remain proprietary, but their focus on innovative solutions in cell separation suggests a strategic pricing approach aimed at meeting the needs of both small laboratories and larger clinical facilities.SynGen Inc. is actively working on designing new products that cater to the evolving needs in regenerative medicine, with plans for launch in upcoming years. The company aims to expand its reach into new markets, particularly targeting regions in Asia and Europe by 2025. The recent funding from the Venture Debt round will be utilized to support these product developments and market expansion initiatives, enabling SynGen to strengthen its position in the global regenerative medicine sector.

## Funding rounds

- Series A, Apr 18, 2012, $5M — Bay City Capital

## Investors

- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series A